Tebu Bio: Drug Discovery

MARCH 27, 2020

“A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing” (March 2020) bioRxiv). For example, a recent study has identified 332 high confidence SARS-CoV-2-human protein-protein interactions (Gordon D.E. All these efforts are […]

Small Molecule 52

Small Molecule Drugs 52

Drug Target Review

APRIL 7, 2025

Advancements in screening technologies for small-molecule drug discovery including cellular assays, computational screening, and biophysics-based methods enhanced by structural biology breakthroughs have improved screening hit rates and facilitated the identification of drug candidates for previously undruggable targets. 2022.02.002.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. The program was initiated in April 2020. References. Hilgenfeld, Febs J.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. Conference Call Information : Date : Thursday, November 5, 2020. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. WALTHAM, Mass., Time : 4:30 p.m.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

JANUARY 19, 2021

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel orally administered first-in-class small molecule that was developed based on an anti-virulence approach targeting Staphylococcus aureus including MRSA. About ALS-4.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

LifeSciVC

JANUARY 16, 2024

Small molecule GLP1s? Small molecules are still in vogue despite IRA headwinds: We continue to hear optimism for the convenience of orals even in indications with high-commercial potential and enriched for CMS coverage (likely to fall in crosshairs of IRA).

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Target Review

SEPTEMBER 25, 2024

Applying our technology has enabled us to develop a new small molecule, TT125-802, and to assign a new role to the epigenetic regulator CBP/p300 as a novel master regulator of non-oncogene resistance. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

DECEMBER 20, 2020

21, 2020 11:00 UTC. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented: “Further to our previous update in September 2020, we are pleased to announce this CTA submission which represents a major development milestone for our ALS-4 antimicrobial program. About ALS-4.

Small Molecule 40

Small Molecule Clinical Trials Trials Treatment 40

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. SAN DIEGO , Oct.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

Drug Target Review

OCTOBER 4, 2023

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs. 52 , 79–91 (2020).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

New Drug Approvals

SEPTEMBER 23, 2024

There are no current small molecule therapies targeting the underlying cause of the disease, leaving a high unmet need for medications that can be used for treating or ameliorating HD. Consequently, there remains a need to identify and provide small molecule compounds for treating or ameliorating HD. 2020-01-02.

Small Molecule 57

Small Molecule RNA DNA Disease 57

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. 19, 2020 /PRNewswire/ — OBI Pharma, Inc. Session Date and Time: Friday, November 20, 2020. Session Date and Time: Friday, November 20, 2020. TAIPEI, Taiwan , Nov.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

MARCH 24, 2021

billion EUR in 2020 (18.9% Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. Our achievements in 2020 are the result of their effort.”. Overall R&D investment up 7% to 3.7

Therapies 52

Therapies Disease Vaccine Small Molecule 52

The Pharma Data

JANUARY 3, 2021

Eprenetapopt is a small molecule that reactivates the mutant and inactivated p53 protein. LX9211 is an oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). Although the combo treatment demonstrated a higher complete remission rate than azacytidine alone, it was not deemed statistically significant.

Small Molecule 52

Small Molecule Trials Vaccine Therapies 52

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

Drug Target Review

NOVEMBER 1, 2023

He formerly worked at EMBL as a postdoctoral fellow from 2017 to 2020 where he discovered the inhibition of ATX with THC. 2020 Jan 1;57(1):372–92. Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode. He is a researcher at University of Oldenburg, Germany. 2018 Jun 13;5.

Clinical Trials 134

Clinical Trials Trials Small Molecule Disease 134

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 11:00 UTC. NASDAQ: CNCE) today reported financial results for the third quarter of 2020. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. LEXINGTON, Mass.–(

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

Drug Target Review

APRIL 7, 2025

Novel mechanisms of action associated with CGTs naturally create dosing effects that apply in very different ways than with traditional small molecule pharmacotherapies. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Bagyinszky E, et al. 21(10):3517.

Clinical Development 59

Clinical Development Clinical Trials Clinical Pharmacology Trials 59

The Pharma Data

FEBRUARY 4, 2021

3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. NORTH CHICAGO, Ill., Gonzalez , chairman and chief executive officer, AbbVie.

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 13:30 UTC. SAN DIEGO–( BUSINESS WIRE )– Vividion Therapeutics , a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer.

Small Molecule 52

Small Molecule Pharmacy Pharmaceuticals Science 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. SAN JOSE, Calif. , The Company’s pipeline is highlighted below: Aridis’ Pipeline.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. Cortexyme’s approach is based on the theory that P.

Small Molecule 62

Small Molecule DNA Disease Trials 62

FDA Law Blog: Biosimilars

JULY 11, 2023

To set the stage for this case, we need to go back to March 2020 , when a new definition of “biological product” threw the world of protein products into a tizzy. And, like it has before , the District Court of D.C. recently grappled with this very question in Ipsen v.

FDA 95

FDA Regulations Production Small Molecule 95

The Pharma Data

OCTOBER 21, 2020

22, 2020 02:59 UTC. The proposed offering is expected to close on October 26, 2020, subject to customary closing conditions. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Small Molecule 40

Small Molecule Treatment Therapies Production 40

The Pharma Data

NOVEMBER 29, 2020

30, 2020 07:00 UTC. Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ? TOKYO & CAMBRIDGE, England–( BUSINESS WIRE )– Eisai Co.,

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 10:45 UTC. –( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. 2020. for the third quarter of 2020. . for the third quarter of 2020. KENILWORTH, N.J.–(

Vaccine 40

Vaccine Trials Treatment Therapies 40

The Pharma Data

DECEMBER 23, 2020

LYT-100 is an anti-fibrotic and anti-inflammatory oral small molecule that has been designed to overcome the tolerability challenges associated with pirfenidone, an anti-inflammatory, anti-fibrotic drug currently on the market. The trial is ongoing in the U.S. and Europe, and PureTech Head of Innovation, Dr. Michael C.

Clinical Trials 52

Clinical Trials FDA Small Molecule Trials 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

MARCH 28, 2024

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. 1 Surprisingly, however, less than one percent of the natural world’s chemical composition has been identified or studied by scientists.

Production 128

Production Drugs Small Molecule Bioinformatics 128

The Pharma Data

NOVEMBER 26, 2020

As of today, Nanoform has two non-GMP lines on the biologics side in addition to the eight CESS ® small molecule nanoparticle technology non-GMP lines. Edward Hæggström, Nanoform CEO: “Small is powerful, also in Bio! HELSINKI , Nov. ” Prof. Finnish time. About Nanoform.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 14:00 UTC. As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About SLV213.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

DECEMBER 2, 2020

2, 2020 — Levels of some small molecules called metabolites in the body may affect your risk of stroke, a new analysis suggests. ” © 2020 HealthDay. Posted: December 2020. WEDNESDAY, Dec. Metabolites come from the food people eat, and they cause chemical processes within the bodies and microbes.

Small Molecule 52

Small Molecule Research Disease 52

The Pharma Data

DECEMBER 15, 2020

16, 2020 14:00 UTC. Validated technology platform translates novel molecules from plants into first-in-class medicines. In our early hit identification work at Enveda, we access the tremendous diversity that exists in natural products from plants, which are often attractive, drug-like small molecules—what we call good hits!”

Small Molecule 52

Small Molecule Production Laboratories Engineering 52

Drug Target Review

DECEMBER 21, 2023

All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines. Consider that all this was in 2020 and AI was still on the side lines as an experiment. Examples of such mechanisms include RBPs, splicing, and relocalisation of mRNAs among many others.

Disease 105

Disease Small Molecule Vaccine Drugs 105

Drug Target Review

JUNE 12, 2023

Chemistry42 is a customisable and fully automated software platform launched in 2020 that integrates generative AI algorithms with computational and medicinal chemistry methods to generate novel molecules with drug-like properties, sometimes in a matter of days. How was ISM6331 generated and optimised using Chemistry42?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92